ade-oleosum inj. a.u.v.
paricalcitol fresenius 5 µg/ml
fresenius medical care nephrologica deutschland gmbh, nemecko - parikalcitol - 87 - varia i
paricalcitol fresenius 2 µg/ml
fresenius medical care nephrologica deutschland gmbh, nemecko - parikalcitol - 87 - varia i
paricalcitol hameln 5 mikrogramov/ml injekčný roztok
siegfried hameln services gmbh - parikalcitol - 87 - varia i
paricalcitol pharmathen 5 mikrogramov/ml
pharmathen s.a., grécko - parikalcitol - 87 - varia i
paricalcitol pharmathen 2 mikrogramy/ml
pharmathen s.a., grécko - parikalcitol - 87 - varia i
paricalcitol xantis 5 mikrogramov/ml
xantis pharma limited, cyprus - parikalcitol - 87 - varia i
paricalcitol xantis 2 mikrogramy/ml
xantis pharma limited, cyprus - parikalcitol - 87 - varia i
rocaltrol 0,25 µg
roche slovensko - kalcitriol - 86 - vitamina, vitagena
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - lieky na liečbu chorôb kostí - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.